United States: Drug Quality And Security Act Gives FDA Authority To Regulate Drug Compounding And Creates Uniform Federal Standards For Distribution

Michael J. Werner is a partner in our Washington, D.C. office

On Nov.18, Congress enacted sweeping changes to the laws governing the safety of the drug supply. The Drug Quality and Security Act (the act) clarifies FDA's authority to regulate drug compounding. It also creates uniform federal standards for key supply chain stakeholders and a national system of serialization to effectively trace drugs throughout the supply chain replacing the existing patchwork of state pedigree rules.

Congress had been working on drug security/traceability for several years. Compounding issues became salient to federal policy makers after a fatal meningitis outbreak last year was caused by drugs produced in a compounding pharmacy.

Compounding Pharmacies as "Outsourcing Facilities"

The act creates a new class of FDA-regulated entities known as "outsourcing facilities." This is a voluntary program — entities can choose whether to undergo FDA review to become classified as an outsourcing facility. Congress' view is that market forces will provide incentives for facilities to participate in the program since hospitals, long-term care facilities and other providers will likely prefer to purchase compounded drugs from regulated entities.

To qualify, the facility must pay user fees to FDA and meet a series of reporting and other quality assurance requirements. Facilities that comply with these provisions "may or may not" obtain prescriptions for identified individual patients. Pharmacies that choose not to participate in this program remain subject to state pharmacy licensure rules.

The act defines compounding as "the combining, admixing, mixing, diluting, pooling, reconstituting, or otherwise altering of a marked and approved drug or bulk drug substance to create a drug." The legislation amends the Food, Drug, and Cosmetic Act and allows an entity to be regulated as an outsourcing facility for compounding as long as:

  • Drugs are compounded by or under the direct supervision of a licensed pharmacist.
  • The facility registers with FDA and complies with reporting requirements.
  • The facility does not compound using bulk drug substances (unless, among other requirements, these substances comply with an applicable monograph under the U.S. Pharmacopeia, the National Formulary, or another compendium or pharmacopeia recognized by the secretary of the U.S. Department of Health and Human Services) and its drugs are manufactured by an FDA-registered establishment.
  • Other ingredients used in compounding the drug must comply with the standards of the applicable U.S. Pharmacopeia or National Formulary monograph, if a monograph exists, or of another compendium or pharmacopeia recognized by the secretary.
  • The drug does not appear on a list published by FDA of unsafe or ineffective drugs.
  • The drug is not "essentially a copy" of one or more marketed drugs.
  • The drug does not appear on the FDA list of drugs or categories of drugs that present "demonstrable difficulties" for compounding.
  • The compounding pharmacist demonstrates that he or she will use controls comparable to the controls applicable under any applicable risk evaluation and mitigation strategy (REMS).
  • The drug will not be sold or transferred by an entity other than the outsourcing facility.
  • The drug is compounded in a facility that has paid user fees.
  • The label of the drug states, "This is a compounded drug" or contains "a reasonable comparable alternative statement" as specified by the secretary, as well as the name of the outsourcing facility, the lot or batch number of the drug, dosage form and strength, and other key information.

The law also clarifies that any misleading advertising or promotion of a compounded drug deems the drug misbranded. It also expressly prohibits the resale of a compounded drug that is labeled "not for resale" and the intentional falsification of a prescription with respect to a compounded drug.

Outsourcing facilities are required to register with FDA each year. The list of registered facilities will be made public by FDA. Every six months, the facility must submit a report to FDA that:

  • identifies the drugs compounded at the facility
  • provides additional information about the drugs including the active ingredient (and its source), the National Drug Code number of the source drug or bulk active ingredient, the strength of the active ingredient per unit and the number of units produced

Outsourcing facilities will be subject to FDA inspection based upon a "risk-based schedule" to be developed by the agency. Inspection determinations will be based on the known safety risks of outsourcing facilities based on compliance history, record and nature of recalls linked to the facility, and the inherent risk of the drugs compounded at the facility. Facilities are also required to submit adverse event reports to FDA.

Outsourcing facilities must pay user fees consisting of an annual establishment fee and a re-inspection fee. The fees are each $15,000 multiplied by an inflation adjustment. An outsourcing facility with gross annual sales of $1 million or less (ending April 1 of the preceding fiscal year) will only pay 33 percent of the amount otherwise owed. The establishment fee for all other facilities is subject to a "small business adjustment" to account for the number of facilities with discounted fees. Failure to pay user fees deems any drug manufactured or compounded at that facility misbranded.

Enhanced Communication

State boards of pharmacy are required to submit to FDA any actions taken against compounding pharmacies or express concerns that a compounding pharmacy may be acting contrary to one or more FDA requirements. This includes warning letters, sanctions, or suspension or revocation of a state license. FDA is required to notify a state pharmacy board if it finds that a compounding pharmacy is violating federal regulations.

Drug Distribution Security

The act creates a new federal system of traceability for prescription drugs. Supply chain stakeholders had argued for many years that the current state-by-state system of pedigree rules was cumbersome and did not take advantage of improved information technologies that can trace packages in distribution across the country.

Certain products are exempt from the act's provisions. They are the following:

  • blood and blood components intended for transfusion
  • radioactive drugs and radioactive biologics
  • intravenous products
  • medical gas
  • compounded drugs
  • dispensing drugs pursuant to a prescription
  • medical convenience kits and combination products not approved as drugs or biologics
  • sterile water and products intended for irrigation

The act assigns regulatory requirements based on changes in ownership of the package, rather than simply change of possession. It requires that each owner (such as the manufacturer, wholesale distributor, or dispenser) transfer to a subsequent owner traceability information with respect to each transaction. The three types of information to be provided are:

1."Transaction Information" — the proprietary or established name or names of the product; the strength and dosage form of the product; the National Drug Code number of the product; the container size; the number of containers; the lot number of the product; the date of the transaction; the date of the shipment if more than 24 hours after the date of the transaction; the business name and address of the person from whom ownership is being transferred; and the business name and address of the person to whom ownership is being transferred

2."Transaction Statement" — paper or electronic, which states the entity:

  • is authorized as required under the [act]
  • received the product from a person that is authorized as required under the [act]
  • received transaction information and a transaction statement from the prior owner of the product
  • did not knowingly ship a suspect or illegitimate product
  • had systems and processes in place to comply with verification requirements
  • did not knowingly provide false transaction information
  • did not knowingly alter the transaction history

3."Transaction History" — paper or electronic statement that includes the transaction information for each prior transaction going back to the manufacturer of the product

These traceability requirements generally require products to be tracked at the lot level. In general, a product owner must provide transaction information, a transaction statement and transaction history to the subsequent owner for each transaction, and capture and maintain the information for six years. This obligation begins on Jan. 1, 2015, for manufacturers, wholesaler distributors and repackagers; and on July 1, 2015, for dispensers. A trading partner is required to provide this information to the secretary or other appropriate official in the event of a recall or an investigation of a product that is suspect. Beginning Jan. 1, 2015, trading partners must also maintain systems and processes for investigating and quarantining products that are suspect or illegitimate.

The act requires members of the supply chain to only transact with registered or licensed entities starting Jan. 1, 2015, with a phase-in period for dispensers starting on July 1, 2015.

The legislation implements a national unit level serialization program by requiring manufacturers to use a product identifier with each individual package and homogenous case of the product in four years. Repackagers must affix product identifiers within five years.

The "standard numerical identifier" is a set of numbers or characters used to uniquely identify each package or homogenous case that is composed of the National Drug Code that corresponds to the specific product (including the particular package configuration) combined with a unique alphanumeric serial number of up to 20 characters. According to the act, unless the secretary allows other technologies, it must be included in a two-dimensional data matrix barcode when affixed to, or imprinted upon, a package; and included in a linear or two-dimensional data matrix barcode when affixed to, or imprinted upon, a homogeneous case. It can be verified using human-readable or machine-readable methods.

The act requires interoperable electronic unit level product tracing in 10 years. The unit level product tracing requirements will be based on guidance issued by FDA regarding unit level product tracing and standards for interoperable data exchange, which, in turn, will be based on public meetings and pilot projects that will evaluate feasibility and cost.

Wholesale Distributor and Third-Party Logistics Provider Licensing

The act establishes uniform national licensing standards for wholesale distributors and third-party logistics providers and authorizes FDA to charge user fees to enforce these standards. The secretary is required to establish the standards within two years. States may continue to license wholesale distributors and third-party logistics providers but must do so using the federal standards. In states that do not establish state licensing programs, entities will receive a federal license from FDA.

Preemption

The act preempts state laws and regulations that establish "any requirements for tracing products through the distribution system" (such as pedigree rules) that are "inconsistent with, more stringent than, or in addition to" the requirements of the act.

The act also preempts all state regulations related to wholesale distributor or third-party logistics provider licensure that are "inconsistent with, less stringent than, directly related to, or covered by the standards and requirements of the Act."

Implementing Regulations

FDA will begin developing regulations on both compounding and traceability shortly. On compounding, FDA will be developing regulations to implement many of the bill's provisions including:

  • how to determine if a drug presents "demonstrable difficulties" for compounding
  • the process for registration of outsourcing facilities
  • creation of the "risk-based schedule" for inspection
  • creation of an advisory committee on compounding
  • establishing the amount of the establishment fee and re-inspection fee

Regarding traceability, there are several actions FDA will be taking to implement the legislation including:

  • FDA will issue a draft guidance within one year establishing the standards for the interoperable exchange of transaction information, history and statements.
  • FDA will issue guidance within two years regarding process for waivers for the manufacturer, wholesaler or dispenser and exceptions for product identifier requirements.
  • After 10 years, the requirement to perform unit level tracing goes into effect (including passing transaction information, verification requirements, etc.) FDA is required to provide for "alternative methods of compliance" with any of these requirements.
  • FDA is required to hold five public meetings, including meetings on the system attributes necessary to enable secure tracing of a product at the unit level as well as on interoperable standards. Eighteen months after this public meeting, FDA is required to issue a final guidance that outlines and makes recommendations on these issues.
  • FDA is required to establish "one or more" pilot projects with supply chain stakeholders to "explore and evaluate" methods to enhance safety and security of the supply chain.
  • Beginning one year after enactment, wholesale distribution establishments are required to report information annually to FDA. FDA will need to create and identify the format and substance of the report. Subsequently, FDA will develop a public database with this information.
  • FDA will need to establish licensing fees to support the federal licensing programs for wholesale distributors and third-party logistics providers.
  • Not less than two years after enactment, FDA must issue regulations regarding licensing standards, including revocation and re-issuance, for distributors and third-party logistics providers.

All stakeholders in the drug supply chain should monitor and strongly consider participating in these developments in the weeks ahead. FDA's implementation of these provisions will greatly impact regulation of the supply chain.  

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.